The features of a humoral response in patients with COVID-19

DOI: https://doi.org/10.29296/25877305-2021-12-01
Download full text PDF
Issue: 
12
Year: 
2021

L. Generalova(1); Professor O. Burgasova(1, 3), MD; V. Gushchin(2, 3), Candidate of Biological
Sciences; Professor L. Kolobukhina(3), MD; V. Bakalin(1); V. Tetova(1), Candidate of Medical Sciences; M.
Odnoralov(1), E. Generalov(2), Candidate of Physical and Mathematical Sciences (1)Peoples Friendship
University of Russia, Moscow (2)M.V. Lomonosov Moscow State University (3)N.F. Gamaleya National Research
Center for Epidemiology and Microbiology, Moscow

The article provides a brief overview of the accumulated data on humoral and T-cell responses to SARS-CoV-2 in patients with COVID-19. It characterizes an antibody response, the neutralizing capacity of immunoglobulin G to the receptor-binding domain (RBD), the timing of antibody elimination, and avidity. RBD has been shown to be the main target for the production of neutralizing antibodies. Analysis and further study of the determinants of SARS-CoV-2 humoral response in patients with COVID-19 will be able to develop more advanced diagnostic techniques.
Keywords: 
infectious diseases
antiviral immunity
antibodies to COVID-19
neutralizing antibodies
timing of immune response
antibodies to the S protein
RBD
N-protein

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Russell B., Moss C., George G. et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancermedicalscience. 2020; 14: 1022. DOI: 10.3332/ecancer.2020.1022
  2. Kozlov V.A., Savchenko A.A., Kudrjavtsev I.V. i dr. Klinicheskaja immunologija. Krasnojarsk: Polikor, 2020; 386 s. [Kozlov V.A., Savchenko A.A., Kudryavtsev I.V. et al. Clinical immunology. Krasnoyarsk: Polikor, 2020; 386 s. (in Russ.)]. DOI: 10.17513/np.438
  3. Haslbauer J., Matter M., Stalder A. et al. Histomorphological patterns of regional lymph nodes in COVID-19 lungs. Pathologe. 2021; 42 (1): 89–97. DOI: 10.1007/s00292-021-00945-6
  4. Moon C. Fighting COVID-19 exhausts T cells. Nat Rev Immunol. 2020; 20: 277. DOI: 10.1038/s41577-020-0304-7
  5. Shi Y., Wang Y., Shao C. et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020; 27: 1451–4. DOI: 10.1038/s41418-020-0530-3
  6. Guo L., Ren L., Yang S. et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis. 2020; 71 (15): 778–85. DOI: 10.1093/cid/ciaa310
  7. Gudima G.O., Haitov R.M., Kudlaj D.A. i dr. Molekuljarno-immunologicheskie aspekty diagnostiki, profilaktiki i lechenija koronavirusnoj infektsii. Immunologija. 2021; 42 (3): 198–210 [Gudima G.O., Khaitov R.M., Kudlay D.A. et al. Molecular immunological aspects of diagnostics, prevention and treatment of coronavirus infection. Immunologiya. 2021; 42 (3): 198-210 (in Russ.)]. DOI: 10.33029/0206-4952-2021-42-3-198-210
  8. Zhao J., Yuan Q., Wang H. et al. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020; 71 (16): 2021–34. DOI: 10.1093/cid/ciaa344
  9. Wu L.P., Wang N.C., Chang Y.H. et al. Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis. 2007; 13: 1562–4. DOI: 10.3201/eid1310.070576
  10. Qu J., Wu C., Li X. et al. Profile of immunoglobulin G and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020; 71 (16): 2255–8. DOI: 10.1093/cid/ciaa489
  11. Wolfel R., Corman V., Guggemos W. et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020; 581 (7809): 465–9. DOI: 10.1038/s41586-020-2196-x
  12. Dan J., Mateus J., Kato Y.et al. Immunological memory to SARS-CoV-2 assessed for greater than six months after infection. bioRxiv. 2020.11.15.383323. DOI: 10.1101/2020.11.15.383323
  13. Qu J., Wu C., Li X. et al. Profile of Immunoglobulin G and IgM Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020; 71 (16): 2255–8. DOI: 10.1093/cid/ciaa489
  14. Wölfel R., Corman M., Guggemos W. et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020; 581: 465–9. DOI: 10.1038/s41586-020-2196-x
  15. Denning D., Kilcoyne A., Ucer C. Non-infectious status indicated by detectable IgG antibody to SARS-CoV-2. Br Dent J. 2020; 229: 521–4. DOI: 10.1038/s41415-020-2228-9
  16. Addetia A., Crawford K.H.D., Dingens A. et al. Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate. J Clin Microbiol. 2020; 58 (11): e02107-20. DOI: 10.1128/JCM.02107-20
  17. Pray I., Gibbons-Burgener S., Rosenberg A. et al. COVID-19 outbreak at an overnight summer school retreat – Wisconsin, July-August 2020. MMWR Morb Mortal Wkly Rep. 2020; 69 (43): 1600–4. DOI: 10.15585/mmwr.mm6943a4
  18. Jeffery-Smith A., Iyanger N., Williams S. et al. Antibodies to SARS-CoV-2 protect against re-infection during outbreaks in care homes, September and October 2020. Euro Surveill. 2021; 26 (5): 2100092. DOI: 10.2807/1560-7917
  19. Li K., Huang B., Wu M. et al. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. Nat Commun. 2020; 11 (1): 6004. DOI: 10.1038/s41467-020-19943-y
  20. Haddad N., Nguyen D., Kuruvilla M. et al. Elevated SARS-CoV-2 Antibodies Distinguish Severe Disease in Early COVID-19 Infection. bioRxiv. 2020.12.04.410589. DOI: 10.1101/2020.12.04.410589
  21. Jiang S., Hillyar C., Du L. et al. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses. Trends Immunol. 2020; 41 (5): 355–9. DOI: 10.1016/j.it.2020.03.007
  22. Benner S., Patel E., Laeyendecker O. et al. SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors. J Infect Dis. 2020; 222 (12): 1974–84. DOI: 10.1093/infdis/jiaa581
  23. Valdez-Cruz N., Garcia-Hernández E., Espitia C. et al. Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment. Microb Cell Fact. 2021; 20 (1): 88. DOI: 10.1186/s12934-021-01576-5
  24. Chia W.N., Zhu F., Ong S.W.X. et al. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. [published correction appears in Lancet Microbe. 2021; 2 (5): e179]. Lancet Microbe. 2021; 2 (6): e240–e249. DOI: 10.1016/S2666-5247(21)00025-2
  25. Kening L., Bin H., Min W. et al. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. Nat Commun. 2020; 11 (1): 6044. DOI: 10.1038/s41467-020-19943-y
  26. Jiang H., Li Y., Zhang H. et al. SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses. Nat Commun. 2020; 11 (1): 3581. DOI: 10.1038/s41467-020-17488-8
  27. Whitcombe A., McGregor R., Craigie A. et al. Comprehensive analysis of SARS-CoV-2 antibody dynamics in New Zealand. Clin Transl Immunol. 2021; 10 (3): e1261. DOI: 10.1002/cti2.1261
  28. Guo L., Ren L., Yang S. et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clin Infect Dis. 2020; 71 (15): 7778–85. DOI: 10.1093/cid/ciaa310
  29. Kohmer N., Westhaus S., Rühl C. et al. Clinical performance of different SARS-CoV-2 IgG antibody tests. J Med Virol. 2020; 92 (10): 2243–7. DOI: 10.1002/jmv.26145
  30. Li G., Chen X., Xu A. Profile of specific antibodies to the SARS-associated coronavirus. N Engl J Med. 2003; 349 (5): 508–9. DOI: 10.1056/NEJM200307313490520
  31. Qu J., Wu C., Li X. et al. Profile of IgG and IgM antibodies against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020; 27: ciaa489. DOI: 10.1093/cid/ciaa489
  32. Deeks J., Dinnes J., Takwoingi Y. et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev. 2020; 6 (6): CD013652. DOI: 10.1002/14651858.CD013652
  33. Long Q., Tang X., Shi Q. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020; 26: 1200–4 DOI: 10.1038/s41591-020-0965-6
  34. Lei Q., Li Y., Hou H. et al. Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections. Allergy. 2021; 76 (2): 551–61. DOI: 10.1111/all.14622
  35. Chia W., Zhu F., Ong S. et al. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. [published correction appears in Lancet Microbe. 2021; 2 (5): e179]. Lancet Microbe. 2021; 2 (6): e240–e249. DOI: 10.1016/S2666-5247(21)00025-2
  36. Wang C., Li W., Drabek D. et al.A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020; 11 (1): 2251. DOI: 10.1038/s41467-020-16256-y